Pasar al contenido principal

Josep A Villena Delgado

I earned my PhD in Biological Sciences at the University of Barcelona and I am currently a principal investigator of the Research Unit in Diabetes and Metabolism, where I lead the Laboratory of Metabolism and Obesity. The research carried out by my team focuses on understanding the mechanisms that regulate energy balance and glucose homeostasis, and how alterations in such mechanisms contribute to the pathogenesis of metabolic disorders, such as obesity, insulin resistance or diabetes. I am also coordinator and professor of the endocrine diseases section of the VHIR’s Master in Translational Biomedical Research.

Instituciones de las que forman parte

Investigador/a principal
Diabetes y Metabolismo
Vall Hebron Institut de Recerca

Josep A Villena Delgado

Instituciones de las que forman parte

Investigador/a principal
Diabetes y Metabolismo
Vall Hebron Institut de Recerca

I earned my PhD in Biological Sciences at the University of Barcelona and I am currently a principal investigator of the Research Unit in Diabetes and Metabolism, where I lead the Laboratory of Metabolism and Obesity. The research carried out by my team focuses on understanding the mechanisms that regulate energy balance and glucose homeostasis, and how alterations in such mechanisms contribute to the pathogenesis of metabolic disorders, such as obesity, insulin resistance or diabetes. I am also coordinator and professor of the endocrine diseases section of the VHIR’s Master in Translational Biomedical Research.

I obtained a degree in Biological Sciences by the University of Barcelona, where I also earned my PhD in Biology. The work of my PhD thesis focused on the identification of the transcription factors involved in the regulation of mitochondrial biogenesis. From 1999 to 2000, I worked as a postdoctoral researcher at the Rangueil University Hospital/CNRS (Toulouse, France) to investigate the role of adipose precursor cells on the immune function. In 2000, I moved to the University of California (Berkeley, USA). There, my work was dedicated to unveil the mechanisms involved in the differentiation and function of adipose cells and their impact on body weight and glucose homeostasis. The results of my work contributed to elucidate the function of Pref-1 as an inhibitor of adipogenesis and the identification of a new triglyceride lipase (Desnutrin/ATGL). In 2004. I joined The Scripps Research Institute (La Jolla, USA) as a research associate, where I worked on the role of Estrogen-Related Receptors in the control of mitochondrial biogenesis and the thermogenic function of brown adipose tissue. In 2007, after being awarded a “Ramon y Cajal” researcher position, I joined VHIR as a principal investigator. Since then, I lead the Laboratory of Metabolism and Obesity, integrated within the Unit of Diabetes and Metabolism. The most recent research of my team has allowed to precisely define the role of PGC-1s co-activators on adipose tissue mitochondrial biogenesis in response to anti-diabetic drugs or nutritional interventions, such a caloric restriction. Moreover, our work on cardiac metabolism in the context of diabetes led to the identification of ERRgamma as a factor potentially involved in the pathogenesis of diabetic cardiomyopathy. Our current research lines focus on the identification of the factors driving the resolution of obesity-associated meta-inflammation, which is considered to be at the origin of most of the comorbidities associated with this metabolic disease.

As a principal investigator, I have led numerous research projects funded by public (MINECO, MICINN) and private (La Marató de TV3, Fundació La Caixa) funding bodies. Among others, I currently coordinate OBESIMM, an international multicentric study aimed at defining the effects that intermittent feeding has on inflammation and the immune function of obese individuals. I am also a member of ADIPOBROAD, a national network of research groups for the study of adipose tissue plasticity and its impact on human health, as well as a member of the Spanish Society of Biochemistry and Molecular Biology, where I coordinate the study group on Metabolic Regulation and Nutrition.

Proyectos

Mecanismos moleculares de la restricción calórica en tejido adiposo blanco

IP: Josep A Villena Delgado
Colaboradores: Rosario Pardo Diaz
Entidad financiadora: Ministerio de Ciencia e Innovación-MICINN
Financiación: 75020
Referencia: SAF2011-23886
Duración: 01/01/2012 - 30/06/2013

Ministerio de Ciencia

Papel del coactivador PGC-1b en tejido adiposo blanco y su contribución al desarrollo de la obseidad y la diabetes de tipo 2

IP: Josep A Villena Delgado
Colaboradores: Miriam Izquierdo Sans
Entidad financiadora: Ministerio de Ciencia e Innovación-MICINN
Financiación: 42996.39
Referencia: BES-2009-013411
Duración: 01/09/2009 - 31/08/2013

Ministerio de Ciencia

Implication of Estrogen-Related Receptors in the ethiology diabetic cardiomypathy: identification of ERRs as potential pharmacological targets for treatment of diabetic cardiomyopathy

IP: Josep A Villena Delgado
Colaboradores: Marisol Ruiz Meana
Entidad financiadora: Fundació La Marató de TV3
Financiación: 199138
Referencia: MARATV3/2008/082610
Duración: 19/01/2009 - 18/01/2012

Papel del coactivador PGC-1 beta en tejido adiposo blanco y su contribución al desarrollo de la obesidad y la diabetes de tipo 2

IP: Josep A Villena Delgado
Colaboradores: Rosario Pardo Diaz
Entidad financiadora: Ministerio de Ciencia e Innovación-MICINN
Financiación: 168190
Referencia: SAF2008-03644
Duración: 01/01/2009 - 31/03/2012

Ministerio de Ciencia

Noticias relacionadas

El proyecto europeo, en el que participa Vall d’Hebron, favorecerá el diagnóstico personalizado y estrategias terapéuticas innovadoras en pacientes con la enfermedad.

La Unidad de Tratamiento Integral de la Obesidad Pediátrica ha recibido la acreditación de centro de excelencia de la Asociación Europea para el Estudio de la Obesidad, consolidando un modelo que ofrece tratamiento en todas las etapas de la vida

Esta inversión de EIT Health en el proyecto permitirá a D-Sight avanzar en el desarrollo clínico de su innovador tratamiento para las primeras fases de la retinopatía diabética.

Profesionales relacionados

Alba Torija Recasens

Alba Torija Recasens

Investigador predoctoral
Nefrología y Trasplante Renal
Leer más
Carmina Castellano Tejedor

Carmina Castellano Tejedor

Investigador sénior
Investigación en Envejecimiento, Fragilidad y Transiciones en Barcelona
Leer más
Concepció Jacobs Cachá

Concepció Jacobs Cachá

Investigador/a principal
Bioquímica Clínica, Vehiculización de Fármacos y Terapia
Leer más
Xavier Serra Ruiz

Xavier Serra Ruiz

Técnico de investigación
Fisiología y Fisiopatología Digestiva
Leer más

Suscríbete a nuestros boletines y forma parte de la vida del Campus

Vall d'Hebron Barcelona Hospital Campus es un parque de referencia mundial donde la asistencia, la investigación, la docencia y la innovación se dan la mano.